- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07942025
90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Efficacy and Long-Term Outcomes of Yttrium-90 Treatment as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study
This multicenter observational study will evaluate long-term outcomes in patients with initially unresectable hepatocellular carcinoma who undergo curative-intent hepatectomy after conversion therapy. The conversion therapy is based on either yttrium-90 selective internal radiation therapy or transarterial chemoembolization. The study includes a retrospective cohort and a prospective observational cohort. The primary outcome is recurrence-free survival after surgery. Overall survival, postoperative pathological features, and perioperative outcomes will also be compared between the two groups.
Visão geral do estudo
Status
Condições
Descrição detalhada
This study includes both retrospective and prospective components. The retrospective cohort will include eligible patients who previously underwent curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. The prospective observational cohort will consecutively enroll eligible patients after curative-intent hepatectomy and follow them prospectively for postoperative outcomes.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Zheyu Zhou
- Número de telefone: +86 18851092739
- E-mail: zzys02910@btch.edu.cn
Locais de estudo
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 102218
- Beijing Tsinghua Changgung Hospital
-
Contato:
- Lin Zhang
- Número de telefone: +86 15699793366
- E-mail: zla02285@btch.edu.cn
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400038
- Southwest Hospital, Army Medical University
-
Contato:
- Hui Zhang
- Número de telefone: +86 02368754000
- E-mail: 13637912611@163.com
-
-
Fujian
-
Fuzhou, Fujian, China, 350025
- Mengchao Hepatobiliary Hospital of Fujian Medical University
-
Contato:
- Wuhua Guo
- Número de telefone: +86 059188110232
- E-mail: guowuhua@aliyun.com
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510630
- The First Affiliated Hospital of Jinan University
-
Contato:
- Chengzhi Li
- Número de telefone: +86 02038688888
- E-mail: lichengzhi@jnu.edu.cn
-
-
Liaoning
-
Shenyang, Liaoning, China, 110001
- The First Hospital of China Medical University
-
Contato:
- Haibo Shao
- Número de telefone: +86 02483283333
- E-mail: haiboshao@aliyun.com
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Contato:
- Xin Zheng
- Número de telefone: +86 02985323112
- E-mail: xin.zheng.xjtu@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
The study population consists of patients with initially unresectable HCC treated at participating centers who undergo curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. All consecutive patients meeting the predefined eligibility criteria will be included. Patients identified from historical records will form the retrospective cohort, while patients enrolled after study initiation will form the prospective observational cohort.
Descrição
Inclusion Criteria:
- Initially unresectable primary liver cancer.
- Underwent curative-intent hepatectomy following conversion therapy based on 90Y-SIRT or TACE.
- Postoperative histopathological examination confirmed HCC.
Exclusion Criteria:
- Received conversion therapy based on other locoregional treatments, such as hepatic arterial infusion chemotherapy (HAIC) or external beam radiotherapy (EBRT).
- Presence of extrahepatic metastasis prior to curative-intent hepatectomy.
- Postoperative histopathological diagnosis of intrahepatic cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA).
- Failure to achieve R0 resection.
- Incomplete clinical data.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: OTHER
Coortes e Intervenções
Grupo / Coorte |
|---|
|
90Y-SIRT-Based Conversion Therapy Group
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on yttrium-90 selective internal radiation therapy (90Y-SIRT) and subsequently underwent curative-intent hepatectomy after being deemed resectable. |
|
TACE-Based Conversion Therapy Group
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on transarterial chemoembolization (TACE) and subsequently underwent curative-intent hepatectomy after being deemed resectable. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Postoperative recurrence-free survival (RFS)
Prazo: From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
|
From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postoperative overall survival (OS)
Prazo: From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
|
From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
|
|
|
Pathological complete response (pCR) rate
Prazo: Immediately after curative-intent hepatectomy.
|
pCR is defined as the absence of residual viable tumor cells in the resected specimens. The pCR rate is calculated as the proportion of patients achieving pCR among all patients with evaluable postoperative histopathological assessments. |
Immediately after curative-intent hepatectomy.
|
|
Major pathological response (MPR) rate
Prazo: Immediately after curative-intent hepatectomy.
|
MPR is defined as ≤10% residual viable tumor cells in the resected specimens. The MPR rate is calculated as the proportion of patients achieving MPR among all patients with evaluable postoperative histopathological assessments. |
Immediately after curative-intent hepatectomy.
|
|
Microvascular invasion (MVI) positivity rate
Prazo: Immediately after curative-intent hepatectomy.
|
Immediately after curative-intent hepatectomy.
|
|
|
Satellite nodule positivity rate
Prazo: Immediately after curative-intent hepatectomy.
|
Immediately after curative-intent hepatectomy.
|
|
|
Postoperative complication rate
Prazo: Perioperatively, from curative-intent hepatectomy through hospital discharge.
|
The occurrence and type of postoperative complications will be recorded, and their severity will be graded according to the Clavien-Dindo classification. Bile leakage and post-hepatectomy liver failure (PHLF) will also be graded according to the ISGLS criteria. |
Perioperatively, from curative-intent hepatectomy through hospital discharge.
|
Outras medidas de resultado
Medida de resultado |
Prazo |
|---|---|
|
Percentage change in tumor markers
Prazo: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
|
Percentage change in maximum tumor diameter
Prazo: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Lin Zhang, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- KX26-0904-0317
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified IPD underlying the published results may be made available upon reasonable request after publication, subject to approval by the principal investigator and applicable ethical and institutional requirements.
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .